78. Wang K, Guo D-S, Zhao M-Y, Liu Y (2016) A supramolecular vesicle based on the complexation of p-sulfonatocalixarene with protamine and its trypsin-triggered controllable-release
properties. Chem Eur J 22(4):1475–1483
79. Mourer M, Psychogios N, Laumond G, Aubertin AM, Regnouf-de-Vains JB (2010)
Synthesis and anti-HIV evaluation of water-soluble calixarene-based bithiazolyl podands.
Bioorg Med Chem 18(1):36–45
80. Garcia-Hartjes J, Bernardi S, Weijers CA, Wennekes T, Gilbert M, Sansone F, Casnati A,
Zuilhof H (2013) Picomolar inhibition of cholera toxin by a pentavalent ganglioside GM1oscalix[5]arene. Org Biomol Chem 11(26):4340–4349
81. Paquet V, Zumbuehl A, Carreira EM (2006) Biologically active amphotericin B-calix[4]arene
conjugates. Bioconjug Chem 17(6):1460–1463
82. Colston MJ, Hailes HC, Stavropoulos E, Herve AC, Herve G, Goodworth KJ, Hill AM, Jenner
P, Hart PD, Tascon RE (2004) Antimycobacterial calixarenes enhance innate defense mechanisms in murine macrophages and induce control of Mycobacterium tuberculosis infection in
mice. Infect Immun 72(11):6318–6323
83. Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X,
Raymond E, Hoye TR, Mayo KH (2012) Antitumor agent calixarene 0118 targets human
galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 55(11):5121–5129
84. de Fatima A, Fernandes S, Sabino A (2009) Calixarenes as new platforms for drug design.
Curr Drug Discov Technol 6(2):151–170
85. Yousaf A, Hamid SA, Bunnori NM, Ishola AA (2015) Applications of calixarenes in cancer
chemotherapy: facts and perspectives. Drug Des Devel Ther 9:2831–2838
86. Naseer MM, Ahmed M, Hameed S (2017) Functionalized calix[4]arenes as potential therapeutic agents. Chem Biol Drug Des 89(2):243–256
87. Wang K, Guo D-S, Zhang H-Q, Li D, Zheng X-L, Liu Y (2009) Highly effective binding of
viologens by p-sulfonatocalixarenes for the treatment of viologen poisoning. J Med Chem
52(20):6402–6412
88. Bhasikuttan AC, Mohanty J (2017) Detection, inhibition and disintegration of amyloid fibrils:
the role of optical probes and macrocyclic receptors. Chem Commun 53(19):2789–2809
89. Shinde MN, Barooah N, Bhasikuttan AC, Mohanty J (2016) Inhibition and disintegration
of insulin amyloid fibrils: a facile supramolecular strategy with p-sulfonatocalixarenes. Chem
Commun 52(14):2992–2995
90. Xu Z, Jia S, Wang W, Yuan Z, Jan Ravoo B, Guo D-S (2018) Heteromultivalent
peptide recognition by co-assembly of cyclodextrin and calixarene amphiphiles enables
inhibition of amyloid fibrillation. Nat Chem 11(1):86–93
91. Daze KD, Pinter T, Beshara CS, Ibraheem A, Minaker SA, Ma MCF, Courtemanche RJM,
Campbell RE, Hof F (2012) Supramolecular hosts that recognize methyllysines and disrupt the
interaction between a modified histone tail and its epigenetic reader protein. Chem Sci
3(9):2695–2699
92. Gawarammana IB, Buckley NA (2011) Medical management of paraquat ingestion. Br J Clin
Pharmacol 72(5):745–757
93. Wang G-F, Ren X-L, Zhao M, Qiu X-L, Qi A-D (2011) Paraquat detoxification with
p-sulfonatocalix-[4]arene by a pharmacokinetic study. J Agric Food Chem 59(8):4294–4299
8 Supramolecular Medicine of Diverse Calixarene Derivatives
229
properties. Chem Eur J 22(4):1475–1483
79. Mourer M, Psychogios N, Laumond G, Aubertin AM, Regnouf-de-Vains JB (2010)
Synthesis and anti-HIV evaluation of water-soluble calixarene-based bithiazolyl podands.
Bioorg Med Chem 18(1):36–45
80. Garcia-Hartjes J, Bernardi S, Weijers CA, Wennekes T, Gilbert M, Sansone F, Casnati A,
Zuilhof H (2013) Picomolar inhibition of cholera toxin by a pentavalent ganglioside GM1oscalix[5]arene. Org Biomol Chem 11(26):4340–4349
81. Paquet V, Zumbuehl A, Carreira EM (2006) Biologically active amphotericin B-calix[4]arene
conjugates. Bioconjug Chem 17(6):1460–1463
82. Colston MJ, Hailes HC, Stavropoulos E, Herve AC, Herve G, Goodworth KJ, Hill AM, Jenner
P, Hart PD, Tascon RE (2004) Antimycobacterial calixarenes enhance innate defense mechanisms in murine macrophages and induce control of Mycobacterium tuberculosis infection in
mice. Infect Immun 72(11):6318–6323
83. Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X,
Raymond E, Hoye TR, Mayo KH (2012) Antitumor agent calixarene 0118 targets human
galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 55(11):5121–5129
84. de Fatima A, Fernandes S, Sabino A (2009) Calixarenes as new platforms for drug design.
Curr Drug Discov Technol 6(2):151–170
85. Yousaf A, Hamid SA, Bunnori NM, Ishola AA (2015) Applications of calixarenes in cancer
chemotherapy: facts and perspectives. Drug Des Devel Ther 9:2831–2838
86. Naseer MM, Ahmed M, Hameed S (2017) Functionalized calix[4]arenes as potential therapeutic agents. Chem Biol Drug Des 89(2):243–256
87. Wang K, Guo D-S, Zhang H-Q, Li D, Zheng X-L, Liu Y (2009) Highly effective binding of
viologens by p-sulfonatocalixarenes for the treatment of viologen poisoning. J Med Chem
52(20):6402–6412
88. Bhasikuttan AC, Mohanty J (2017) Detection, inhibition and disintegration of amyloid fibrils:
the role of optical probes and macrocyclic receptors. Chem Commun 53(19):2789–2809
89. Shinde MN, Barooah N, Bhasikuttan AC, Mohanty J (2016) Inhibition and disintegration
of insulin amyloid fibrils: a facile supramolecular strategy with p-sulfonatocalixarenes. Chem
Commun 52(14):2992–2995
90. Xu Z, Jia S, Wang W, Yuan Z, Jan Ravoo B, Guo D-S (2018) Heteromultivalent
peptide recognition by co-assembly of cyclodextrin and calixarene amphiphiles enables
inhibition of amyloid fibrillation. Nat Chem 11(1):86–93
91. Daze KD, Pinter T, Beshara CS, Ibraheem A, Minaker SA, Ma MCF, Courtemanche RJM,
Campbell RE, Hof F (2012) Supramolecular hosts that recognize methyllysines and disrupt the
interaction between a modified histone tail and its epigenetic reader protein. Chem Sci
3(9):2695–2699
92. Gawarammana IB, Buckley NA (2011) Medical management of paraquat ingestion. Br J Clin
Pharmacol 72(5):745–757
93. Wang G-F, Ren X-L, Zhao M, Qiu X-L, Qi A-D (2011) Paraquat detoxification with
p-sulfonatocalix-[4]arene by a pharmacokinetic study. J Agric Food Chem 59(8):4294–4299
8 Supramolecular Medicine of Diverse Calixarene Derivatives
229